|Secondary Protocol No.
||MT2012-22R:Collection of Blood Stem and Progenitor Cells from Healthy Adult Donors for Basic Cancer Research
||The primary objective of this project is to collect normal donor blood and/or bone marrow samples for the study of potential toxicity of novel treatments for hematologic malignancies.
||No treatment is involved in this study. At the time of routine collection, obtain an additional 10 ml aspirate (bone marrow donor) or an additional 10 ml peripheral blood (mobilized peripheral stem cell donor).
||Treatments for blood related cancers such as leukemia and myelodysplastic syndrome (MDS) often have toxic effects on normal blood stem and progenitor cells. Normal blood stem and progenitor cells, such as those routinely collected for clinical bone marrow transplantation, provide an essential resource to investigate potential toxic effects in the research laboratory.
Bone marrow or blood that is donated for this study will be used by researchers at the University of Minnesota to evaluate the effects of novel treatments for blood related cancers on normal blood stem and progenitor cells. Researchers may analyze the growth, gene expression, proteins, or DNA of the bone marrow or blood cells that are collected to analyze how the cells respond to novel cancer treatments.
||Any consenting adult (> 18 years of age) donor undergoing bone marrow harvest or mobilized peripheral blood stem cell collection.
|Applicable Disease Sites
||Acute myeloid leukemia (AML)
||Masonic Cancer Center
||A signed consent and HIPAA authorization are required.